<DOC>
	<DOCNO>NCT00589732</DOCNO>
	<brief_summary>To evaluate angiotensin-converting enzyme ( ACE ) inhibitor angiotensin-converting enzyme receptor blocker ( ARBs ) reduce risk restenosis DES implantation .</brief_summary>
	<brief_title>Valsartan Suppression Plaque Volume Restenosis After Drug-Eluting Stent</brief_title>
	<detailed_description>Stimulation angiotensin II type 1 ( AT1 ) receptors arterial injury promotes vascular smooth muscle cell ( VSMC ) migration , proliferation , extracellular matrix production , lead hope blockade receptor angiotensin-converting enzyme inhibitor ( ACEI ) specific ( AT1 ) receptor antagonist ( ARBs ) might reduce intimal hyperplasia . However , despite confirmatory evidence several animal model restenosis , large scale MERCATOR MARCATOR trial cilazapril balloon angioplasty fail show benefit . In 1999 , Kondo report result randomize pilot trial 100 patient receive Palmaz-Schatz stent randomize receive ACE inhibitor quinapril placebo . The volume neointimal hyperplasia assess IVUS significantly less quinapril control group ( 18 ± 0.6 mm3 vs. 25 ± 0.6 mm3 ; p &lt; 0.05 ) . The quinapril group 's restenosis rate 16 % , quinapril benefit observe patient D/D I/D genotype . Also , study report consecutively treat cohort 1,598 stented patient , note ACE inhibitor usage time stenting reduce risk subsequent revascularization dramatically ( adjust odds ratio , 0.46 ; p = 0.001 ) . In ValPREST trial single-center randomized trial patient receive stent type B2/C lesion , compare valsartan ( ARV ) 80 mgs daily open treatment , patient randomize valsartan 19 % incidence restenosis compare 39 % open treatment arm ( p = 0.005 ) . Recently , several randomize study conduct compare safety efficacy two lead drug-eluting stent ( DES ) . However , data association ARBs suppression neointimal hyperplasia limit DES era . Therefore , pivotal randomize study warrant .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>1 . Clinical 1 ) Patients angina documented ischemia patient document silent ischemia 2 ) Patients eligible intracoronary stenting 3 ) Age &gt; 18 year , &lt; 75 age 4 ) Preserved left ventricular ejection fraction ( &gt; 40 % ) 5 ) Written inform consent study protocol 6 ) Patients hemodynamic stability appropriate blood pressure , suitable administration valsartan 160mg 2 . Angiographic : Patients 1 ) Significant ischemic narrowing ( target vessel ) 1 . De novo coronary lesion ( restriction lesion length ) 2 . Percent diameter stenosis ≥50 % visual estimate 3 . Reference vessel size ≥2.5 mm visual estimation 4 . Lesions suitable stenting And/Or 2 ) Nonsignificant nonischemic intermediate narrowing ( nontarget vessel ) 1 . Percent diameter stenosis 20 % ~50 % visual estimate 2 . No objective evidence ischemia 1 . Patients receive Angiotensin convert enzyme inhibitor ( ACEI ) ACEreceptor blocker ( ARBs ) previous week prior enrollment 2 . History bleed diathesis coagulopathy 3 . Pregnant 4 . Known hypersensitivity contraindication contrast agent heparin 5 . Limited lifeexpectancy ( less 1 year ) 6 . Acute STelevation myocardial within 1 week 7 . Characteristics lesion 1 ) Left main disease 2 ) Instent restenosis 3 ) Graft vessel 8 . Hematological disease ( Neutropenia &lt; 3000/mm3 , Thrombocytopenia &lt; 100,000/mm3 ) 9 . Hepatic dysfunction , liver enzyme ( ALT AST ) elevation &gt; 3 time normal 10 . Renal dysfunction , creatinine &gt; 2.0mg/dL 11 . Contraindication aspirin clopidogrel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>stent</keyword>
	<keyword>angiotensin-converting enzyme</keyword>
</DOC>